Physician profile
Douglas D Bailey
NPI 1972669778
$2,572.00
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,299 · 2020: $1,131 · 2021: $142.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $486.53 | 2019-2021 | |
| Amgen INC. | $313.94 | 2019-2020 | |
| Pfizer INC. | $307.25 | 2019-2021 | |
| Novo Nordisk INC | $277.75 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $175.90 | 2019-2021 | |
| Amarin Pharma, INC. | $133.97 | 2020 | |
| Amneal Pharmaceuticals LLC | $112.04 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $109.79 | 2019 | |
| Allergan, INC. | $88.62 | 2019-2020 | |
| Lilly USA, LLC | $77.08 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.34 | 2019-2021 | |
| Astellas Pharma US INC | $68.61 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.08 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $56.28 | 2019 | |
| Sanofi-Aventis U.S. LLC | $46.99 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $41.90 | 2019-2020 | |
| Abbvie INC. | $36.52 | 2021 | |
| Glaxosmithkline, LLC. | $28.85 | 2020 | |
| Antares Pharma, INC. | $22.97 | 2019 | |
| Merck Sharp & Dohme LLC | $19.06 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.84 | 2021 | |
| Strongbridge US INC. | $15.69 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.